[go: up one dir, main page]

FR11C0004I2 - Agonistes du recepteur a 2a n-pyrazole - Google Patents

Agonistes du recepteur a 2a n-pyrazole

Info

Publication number
FR11C0004I2
FR11C0004I2 FR11C0004C FR11C0004C FR11C0004I2 FR 11C0004 I2 FR11C0004 I2 FR 11C0004I2 FR 11C0004 C FR11C0004 C FR 11C0004C FR 11C0004 C FR11C0004 C FR 11C0004C FR 11C0004 I2 FR11C0004 I2 FR 11C0004I2
Authority
FR
France
Prior art keywords
pyrazole
receptor agonists
agonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR11C0004C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of FR11C0004I1 publication Critical patent/FR11C0004I1/fr
Application granted granted Critical
Publication of FR11C0004I2 publication Critical patent/FR11C0004I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR11C0004C 1999-06-22 2011-02-07 Agonistes du recepteur a 2a n-pyrazole Active FR11C0004I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/338,185 US6403567B1 (en) 1999-06-22 1999-06-22 N-pyrazole A2A adenosine receptor agonists
PCT/US2000/040281 WO2000078779A2 (fr) 1999-06-22 2000-06-21 Agonistes du recepteur a2a n-pyrazole

Publications (2)

Publication Number Publication Date
FR11C0004I1 FR11C0004I1 (fr) 2011-03-11
FR11C0004I2 true FR11C0004I2 (fr) 2012-03-16

Family

ID=23323763

Family Applications (1)

Application Number Title Priority Date Filing Date
FR11C0004C Active FR11C0004I2 (fr) 1999-06-22 2011-02-07 Agonistes du recepteur a 2a n-pyrazole

Country Status (27)

Country Link
US (9) US6403567B1 (fr)
EP (1) EP1189916B1 (fr)
JP (1) JP4727880B2 (fr)
KR (1) KR100463300B1 (fr)
CN (1) CN1167709C (fr)
AR (1) AR024441A1 (fr)
AT (1) ATE256141T1 (fr)
AU (1) AU760806B2 (fr)
BE (1) BE2011C004I2 (fr)
BR (1) BRPI0011856B8 (fr)
CA (1) CA2377746C (fr)
CY (1) CY2011002I1 (fr)
DE (2) DE122011000010I1 (fr)
DK (1) DK1189916T3 (fr)
ES (1) ES2209974T3 (fr)
FR (1) FR11C0004I2 (fr)
HK (1) HK1044952B (fr)
IL (2) IL147198A0 (fr)
LU (1) LU91785I2 (fr)
MX (1) MXPA01013325A (fr)
NO (2) NO322457B1 (fr)
NZ (1) NZ516334A (fr)
PT (1) PT1189916E (fr)
TR (1) TR200200588T2 (fr)
TW (1) TWI230161B (fr)
WO (1) WO2000078779A2 (fr)
ZA (1) ZA200200301B (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
USRE47351E1 (en) * 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
WO2001062979A2 (fr) * 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Procede permettant d'identifier des agonistes partiels du recepteur a¿2a?
US20050059068A1 (en) * 2001-05-23 2005-03-17 Stratagene California Compositions and methods using dendrimer-treated microassays
US7262176B2 (en) 2001-08-08 2007-08-28 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
US20030078232A1 (en) * 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
IL163535A0 (en) 2002-02-15 2005-12-18 Cv Therapeutics Inc Polymer coating for medical devices
US7683037B2 (en) * 2002-07-29 2010-03-23 Gilead Palo Alto, Inc. Myocardial perfusion imaging method
US8470801B2 (en) * 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
AU2003268526A1 (en) 2002-09-09 2004-03-29 Cv Therapeutics, Inc. Adenosine a3 receptor agonists
NZ548794A (en) 2004-01-27 2009-07-31 Cv Therapeutics Inc Myocardial perfusion imaging using adenosine receptor agonists
TWI346109B (en) 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
WO2005117910A2 (fr) * 2004-05-26 2005-12-15 Inotek Pharmaceuticals Corporation Derives puriques servant d'agonistes des recepteurs de l'adenosine a1, et leurs procedes d'utilisation
JP5011112B2 (ja) * 2004-09-20 2012-08-29 イノテック ファーマシューティカルズ コーポレイション プリン誘導体を含有する炎症性疾患の治療用医薬
AU2005295437B2 (en) * 2004-10-20 2011-05-19 Gilead Palo Alto, Inc. Use of A2A adenosine receptor agonists
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0505219D0 (en) * 2005-03-14 2005-04-20 Novartis Ag Organic compounds
JP5042996B2 (ja) * 2005-05-19 2012-10-03 ギリアード・パロ・アルト・インコーポレイテッド Ａ１アデノシンレセプターアゴニスト
AU2006320578B2 (en) * 2005-11-30 2013-01-31 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
ES2593028T3 (es) * 2006-02-03 2016-12-05 Gilead Sciences, Inc. Proceso para preparar un agonista de receptor de adenosina A2A y sus polimorfos
US20070183995A1 (en) * 2006-02-09 2007-08-09 Conopco, Inc., D/B/A Unilever Compounds useful as agonists of A2A adenosine receptors, cosmetic compositions with A2A agonists and a method for using the same
BRPI0710573A2 (pt) * 2006-04-21 2012-02-28 Novartis Ag compostos orgánicos, usos e processos para a preparação dos referidos compostos, bem como composição farmacêutica compreendendo os mesmos
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607951D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
DE102006020349A1 (de) 2006-04-28 2007-10-31 Mahle International Gmbh Kolbenmotor und zugehöriges Betriebsverfahren
US7691825B2 (en) * 2006-06-06 2010-04-06 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor agonists
CA2655310A1 (fr) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Utilisation d'agonistes de recepteur d'adenosine a<sb>2a</sb> dans le traitement d'une ischemie
EP1889846A1 (fr) * 2006-07-13 2008-02-20 Novartis AG Dérivés de purine comme agonistes du recepteur A2a
RU2459626C2 (ru) * 2006-09-01 2012-08-27 Гайлид Сайэнсиз, Инк. Способы и композиции, повышающие переносимость пациентом методов визуализации миокарда
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
EP1903044A1 (fr) * 2006-09-14 2008-03-26 Novartis AG Derivés de l'adénosine en tant qu' agonistes du récepteur A2A
EP2066232A1 (fr) * 2006-09-29 2009-06-10 Cv Therapeutics, Inc. Procédés d'imagerie myocardique chez des patients ayant un historique de maladie pulmonaire
AU2007316715A1 (en) * 2006-11-10 2008-05-15 Novartis Ag Cyclopentene diol monoacetate derivatives
US20080267861A1 (en) * 2007-01-03 2008-10-30 Cv Therapeutics, Inc. Myocardial Perfusion Imaging
WO2008133129A1 (fr) * 2007-04-16 2008-11-06 Santen Pharmaceutical Co., Ltd. Agent thérapeutique pour le glaucome renfermant un agoniste du récepteur a2a de l'adénosine en tant que principe actif
RU2443708C2 (ru) * 2007-05-17 2012-02-27 Си Ви Терапьютикс, Инк. Способ получения агониста рецептора a2a-аденозина и его полиморфных модификаций
JP5349461B2 (ja) * 2007-05-17 2013-11-20 ギリアード・パロ・アルト・インコーポレイテッド Ａ２ａ−アデノシン受容体アゴニストおよびその多形体を調製するための方法
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
US20090207843A1 (en) * 2008-02-15 2009-08-20 Andreasen Flemming S System and method for providing network address translation control in a network environment
JP5709743B2 (ja) * 2008-06-06 2015-04-30 ハーバー セラピューティクス， インコーポレイテッド １７−アルキニル−７−ヒドロキシステロイドおよび関連する化合物の調製方法
CA2737077A1 (fr) * 2008-09-29 2010-04-01 Gilead Sciences, Inc. Combinaisons d'agent de regulation de la frequence cardiaque et d'antagoniste de recepteur a-2-alpha utilisees dans des procedes de tomographie a detecteurs multiples assistee par ordinateur
US7957314B2 (en) * 2008-12-12 2011-06-07 Cisco Technology, Inc. System and method for provisioning charging and policy control in a network environment
PH12012501320A1 (en) 2010-01-11 2013-01-21 Inotek Pharmaceuticals Corp Combination, kit and method of reducing intraocular pressure
EA201290958A1 (ru) 2010-03-26 2013-04-30 Инотек Фармасьютикалз Корпорейшн Способ снижения внутриглазного давления у людей с применением n6-циклопентиладенозина (cpa), производных cpa или их пролекарств
US20130109645A1 (en) 2010-03-31 2013-05-02 The united States of America,as represented by Secretary,Dept.,of Health and Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
US9215588B2 (en) 2010-04-30 2015-12-15 Cisco Technology, Inc. System and method for providing selective bearer security in a network environment
JP2011098990A (ja) * 2011-02-21 2011-05-19 Gilead Palo Alto Inc アデノシン受容体作動薬を使用する心筋灌流イメージング方法
WO2012149196A1 (fr) 2011-04-27 2012-11-01 Reliable Biopharmaceutical Corporation Procédés perfectionnés pour la préparation de régadénoson et nouvelle forme cristalline de celui-ci
CZ308577B6 (cs) 2011-08-18 2020-12-16 Farmak, A. S. Způsob přípravy 2-(4-methoxykarbonylpyrazol-1-yl)adenosinu a 2-(4-ethoxykarbonylpyrazol-1-yl)adenosinu
CZ304053B6 (cs) 2011-08-22 2013-09-04 Farmak, A. S. Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu
LT2807178T (lt) 2012-01-26 2017-08-25 Inotek Pharmaceuticals Corporation (2r,3s,4r,5r)-5-(6-(ciklopentilamino)-9h-purin-9-il)-3,4-dihidroksitetrahidrofuran-2-il) } metilnitrato bevandeniai polimorfai ir jų gavimo būdai
WO2014083580A2 (fr) * 2012-11-30 2014-06-05 Leiutis Pharmaceuticals Pvt. Ltd. Compositions pharmaceutiques de régadénoson
SG11201506882YA (en) 2013-03-15 2015-09-29 Inotek Pharmaceuticals Corp Ophthalmic formulations
EP2789624B1 (fr) 2013-04-11 2020-09-23 AMRI Italy S.r.l. Formes solides stables de regadenoson
CZ305213B6 (cs) 2013-04-29 2015-06-10 Farmak, A. S. Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy
EP3003320A4 (fr) 2013-05-30 2016-10-19 Biophore India Pharmaceuticals Pvt Ltd Nouveau polymorphe de régadénoson
CN104513241B (zh) * 2013-09-30 2017-02-08 浙江海正药业股份有限公司 瑞加德松新中间体及其制备方法和应用
CN104744540A (zh) * 2013-12-26 2015-07-01 上海紫源制药有限公司 一种制备瑞加德松的方法
CN105085593A (zh) * 2014-04-21 2015-11-25 上海紫源制药有限公司 瑞加德松的晶型及其制备方法
US10442832B2 (en) 2015-02-06 2019-10-15 Apicore Us Llc Process of making regadenoson and novel polymorph thereof
US9809617B2 (en) 2015-07-03 2017-11-07 Shanghai Ziyuan Pharmaceutical Co., Ltd. Crystal form of regadenoson and preparation method thereof
CN106397442B (zh) * 2015-07-28 2020-03-27 国药集团国瑞药业有限公司 一种瑞加德松的纯化方法
CA3049856C (fr) 2017-01-13 2021-10-26 Tobishi Pharmaceutical Co., Ltd. Regulateur d'activation des neutrophiles
WO2019191389A1 (fr) 2018-03-29 2019-10-03 Johnson Matthey Public Limited Company Formes à l'état solide de régadénoson, leur utilisation et leur préparation
US10815265B2 (en) 2018-06-29 2020-10-27 Usv Private Limited Process for preparation of regadenoson and polymorphs thereof

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK135130B (da) 1970-12-28 1977-03-07 Takeda Chemical Industries Ltd Analogifremgangsmåde til fremstilling af 2-substituerede adenosinderivater eller syreadditionssalte deraf.
BE787064A (fr) 1971-08-03 1973-02-01 Philips Nv Dispositif magnetique comportant des domaines
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4120947A (en) * 1976-03-31 1978-10-17 Cooper Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases
US4089959A (en) * 1976-03-31 1978-05-16 Cooper Laboratories, Inc. Long-acting xanthine bronchodilators and antiallergy agents
SE7810946L (sv) * 1978-10-20 1980-04-21 Draco Ab Metod att behandla kronisk obstruktiv luftvegssjukdom
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
JPS6299395A (ja) 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd ２−アルキニルアデノシンおよび抗高血圧剤
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4990498A (en) * 1988-04-26 1991-02-05 Temple University-Of The Commonwealth System Of Higher Education 2- and 8-azido(2'-5')oligoadenylates and antiviral uses thereof
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5070877A (en) 1988-08-11 1991-12-10 Medco Research, Inc. Novel method of myocardial imaging
DE3831430A1 (de) 1988-09-15 1990-03-22 Bayer Ag Substituierte 4-heterocyclyloximino-pyrazolin-5-one, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
US5270304A (en) 1988-11-15 1993-12-14 Yamasa Shoyu Kabushiki Kaisha Therapeutic 2-alkynyl adenosine agent for ischemic diseases of the heart or brain
IT1229195B (it) 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
EP0429681B1 (fr) 1989-06-20 1995-09-06 Yamasa Shoyu Kabushiki Kaisha (Yamasa Corporation) Intermediaire de synthese de 2-alkynyladenosine, production de cet intermediaire, production de 2-alkynyladenosine avec cet intermediaire et derive stable de 2-alkynyladenosine
US5032252A (en) 1990-04-27 1991-07-16 Mobil Oil Corporation Process and apparatus for hot catalyst stripping in a bubbling bed catalyst regenerator
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5189027A (en) 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
FR2671356B1 (fr) 1991-01-09 1993-04-30 Inst Nat Sante Rech Med Procede de description des repertoires d'anticorps (ab) et des recepteurs des cellules t (tcr) du systeme immunitaire d'un individu.
JP2740362B2 (ja) 1991-02-12 1998-04-15 ヤマサ醤油株式会社 安定な固体状２‐オクチニルアデノシンおよびその製造法
JP3053908B2 (ja) 1991-06-28 2000-06-19 ヤマサ醤油株式会社 ２‐アルキニルアデノシン誘導体
US5516894A (en) * 1992-03-11 1996-05-14 The General Hospital Corporation A2b -adenosine receptors
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
GB9210839D0 (en) 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
WO1993025677A1 (fr) 1992-06-12 1993-12-23 Garvan Institute Of Medical Research SEQUENCES D'ADN CODANT LES RECEPTEURS HUMAINS DE L'ADENOSINE A1, A2a ET A2b
US5705491A (en) 1992-10-27 1998-01-06 Nippon Zoki Pharmaceutical Co., Ltd. Adenosine deaminase inhibitor
CA2112031A1 (fr) * 1992-12-24 1994-06-25 Fumio Suzuki Derives xanthine
US5477857A (en) 1993-09-10 1995-12-26 Discovery Therapeutics, Inc. Diagnostic uses of hydrazinoadenosines
WO1995011681A1 (fr) 1993-10-29 1995-05-04 Merck & Co., Inc. Antagonistes du recepteur de l'adenosine humaine
AU1823895A (en) * 1994-02-23 1995-09-11 Kyowa Hakko Kogyo Co. Ltd. Xanthine derivative
US5704491A (en) * 1995-07-21 1998-01-06 Cummins-Allison Corp. Method and apparatus for discriminating and counting documents
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US5877180A (en) 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US5854081A (en) * 1996-06-20 1998-12-29 The University Of Patent Foundation Stable expression of human A2B adenosine receptors, and assays employing the same
US5780481A (en) * 1996-08-08 1998-07-14 Merck & Co., Inc. Method for inhibiting activation of the human A3 adenosine receptor to treat asthma
US5776960A (en) * 1996-10-16 1998-07-07 Buckman Laboratories International, Inc. Synergistic antimicrobial compositions containing an ionene polymer and a pyrithione salt and methods of using the same
US5770716A (en) 1997-04-10 1998-06-23 The Perkin-Elmer Corporation Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same
WO1998052611A1 (fr) 1997-05-23 1998-11-26 Nippon Shinyaku Co., Ltd. Preparation medicamenteuse aux fins de la prevention et du traitement des hepatopathies
EP1014995A4 (fr) 1997-06-18 2005-02-16 Aderis Pharmaceuticals Inc Compositions et procedes prevenant les restenoses consecutives a des interventions de revascularisation
US6026317A (en) * 1998-02-06 2000-02-15 Baylor College Of Medicine Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
EP1011608A4 (fr) 1998-06-08 2002-05-15 Epigenesis Pharmaceuticals Inc Composition et procede pour la prevention et le traitement de l'insuffisance cardio-pulmonaire et renale, ou des lesions consecutives a l'ischemie, la liberation d'endotoxines, l'emphyseme pulmonaire ou a l'administration de certains medicaments
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
KR100502757B1 (ko) 1999-08-31 2005-07-22 반더빌트유니버시티 Ａ２ｂ 아데노신 수용체의 선택적인 길항제
US6368573B1 (en) * 1999-11-15 2002-04-09 King Pharmaceuticals Research And Development, Inc. Diagnostic uses of 2-substituted adenosine carboxamides
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6677336B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
WO2001062979A2 (fr) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Procede permettant d'identifier des agonistes partiels du recepteur a¿2a?
US6387913B1 (en) * 2000-12-07 2002-05-14 S. Jamal Mustafa Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US6995148B2 (en) 2001-04-05 2006-02-07 University Of Pittsburgh Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
US6599283B1 (en) 2001-05-04 2003-07-29 Cv Therapeutics, Inc. Method of preventing reperfusion injury
EP1389183B1 (fr) 2001-05-14 2010-03-03 Novartis AG Derives de sulfonamide
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
CA2466477C (fr) * 2001-11-09 2012-10-02 Rao Kalla Antagonistes de recepteur d'adenosine a2b
KR20040068317A (ko) * 2001-12-20 2004-07-30 오에스아이 파마슈티컬스, 인코포레이티드 피리미딘 ａ₂ｂ 선택성 길항 화합물, 그의 합성 방법 및용도
AU2003223497A1 (en) * 2002-04-05 2003-10-27 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
RU2332220C2 (ru) 2002-04-18 2008-08-27 Си Ви Терапьютикс, Инк. Способ снижения частоты сердечных сокращений, включающий введение агониста рецептора аденозина а1 вместе с бета-блокатором, блокатором кальциевых каналов или сердечным гликозидом
US7683037B2 (en) 2002-07-29 2010-03-23 Gilead Palo Alto, Inc. Myocardial perfusion imaging method
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
NZ548794A (en) 2004-01-27 2009-07-31 Cv Therapeutics Inc Myocardial perfusion imaging using adenosine receptor agonists
EP1799221A1 (fr) * 2004-10-15 2007-06-27 Cv Therapeutics, Inc. Procede de prevention et de traitement du remodelage des voies respiratoires et de l'inflammation pulmonaire par le biais d'antagonistes du recepteur d'adenosine a2b
AU2005295437B2 (en) 2004-10-20 2011-05-19 Gilead Palo Alto, Inc. Use of A2A adenosine receptor agonists
BRPI0606662A2 (pt) * 2005-01-12 2010-02-09 King Pharmaceuticals Res & Dev métodos para diagnosticar a disfunção miocárdica, a doença da artéria coronária, a disfunção ventricular causada pela doença da artéria coronária, anormalidades de perfusão, para diagnosticar a presença e avaliar a severidade da doença da artéria coronária e a severidade da disfunção ventricular e a disfunção miocárdica, e, kit
ES2593028T3 (es) * 2006-02-03 2016-12-05 Gilead Sciences, Inc. Proceso para preparar un agonista de receptor de adenosina A2A y sus polimorfos
CA2655310A1 (fr) 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Utilisation d'agonistes de recepteur d'adenosine a<sb>2a</sb> dans le traitement d'une ischemie
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
RU2459626C2 (ru) 2006-09-01 2012-08-27 Гайлид Сайэнсиз, Инк. Способы и композиции, повышающие переносимость пациентом методов визуализации миокарда
EP2066232A1 (fr) 2006-09-29 2009-06-10 Cv Therapeutics, Inc. Procédés d'imagerie myocardique chez des patients ayant un historique de maladie pulmonaire
US20080267861A1 (en) 2007-01-03 2008-10-30 Cv Therapeutics, Inc. Myocardial Perfusion Imaging
JP5349461B2 (ja) 2007-05-17 2013-11-20 ギリアード・パロ・アルト・インコーポレイテッド Ａ２ａ−アデノシン受容体アゴニストおよびその多形体を調製するための方法
WO2009076580A2 (fr) 2007-12-12 2009-06-18 Thomas Jefferson University Compositions et procédés pour le traitement et la prévention de maladies cardiovasculaires
CA2737077A1 (fr) * 2008-09-29 2010-04-01 Gilead Sciences, Inc. Combinaisons d'agent de regulation de la frequence cardiaque et d'antagoniste de recepteur a-2-alpha utilisees dans des procedes de tomographie a detecteurs multiples assistee par ordinateur

Also Published As

Publication number Publication date
US20140073596A1 (en) 2014-03-13
IL147198A (en) 2006-04-10
ZA200200301B (en) 2003-11-26
US7655637B2 (en) 2010-02-02
US20060052332A1 (en) 2006-03-09
HK1044952B (zh) 2005-02-25
TWI230161B (en) 2005-04-01
NO20016350D0 (no) 2001-12-21
AR024441A1 (es) 2002-10-02
DK1189916T3 (da) 2004-03-22
US8569260B2 (en) 2013-10-29
BRPI0011856B8 (pt) 2021-05-25
US6642210B1 (en) 2003-11-04
MXPA01013325A (es) 2002-07-02
KR20020028910A (ko) 2002-04-17
CN1167709C (zh) 2004-09-22
ATE256141T1 (de) 2003-12-15
CA2377746A1 (fr) 2000-12-28
JP2003506461A (ja) 2003-02-18
US20130058866A1 (en) 2013-03-07
HK1044952A1 (en) 2002-11-08
NO2011002I2 (no) 2012-10-22
CN1358191A (zh) 2002-07-10
PT1189916E (pt) 2004-03-31
LU91785I2 (fr) 2011-03-31
NO2011002I1 (no) 2011-03-07
AU760806B2 (en) 2003-05-22
CY2011002I2 (el) 2012-01-25
US20110144320A1 (en) 2011-06-16
BE2011C004I2 (fr) 2019-05-21
US20100160620A1 (en) 2010-06-24
BR0011856B1 (pt) 2014-06-17
US9045519B2 (en) 2015-06-02
NO20016350L (no) 2002-02-18
CY2011002I1 (el) 2012-01-25
AU7132400A (en) 2001-01-09
WO2000078779A3 (fr) 2001-03-15
US7183264B2 (en) 2007-02-27
DE60007127T2 (de) 2004-09-16
KR100463300B1 (ko) 2004-12-23
IL147198A0 (en) 2002-08-14
US8278435B2 (en) 2012-10-02
DE122011000010I1 (de) 2011-06-16
CA2377746C (fr) 2007-04-10
US20040038928A1 (en) 2004-02-26
FR11C0004I1 (fr) 2011-03-11
JP4727880B2 (ja) 2011-07-20
TR200200588T2 (tr) 2002-09-23
US6403567B1 (en) 2002-06-11
EP1189916A2 (fr) 2002-03-27
EP1189916B1 (fr) 2003-12-10
WO2000078779A2 (fr) 2000-12-28
US7144872B2 (en) 2006-12-05
DE60007127D1 (de) 2004-01-22
ES2209974T3 (es) 2004-07-01
BR0011856A (pt) 2004-02-10
NO322457B1 (no) 2006-10-09
NZ516334A (en) 2004-05-28
US20070203090A1 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
FR11C0004I2 (fr) Agonistes du recepteur a 2a n-pyrazole
FR10C0006I2 (fr) Agonistes du recepteur beta 2-adrenergique
MA25403A1 (fr) Ligandes de recepteur de melanocortine
DK1446379T3 (da) Arylanilin-beta2-adrenergiske receptoragonister
DE60026169D1 (de) Selektive neurokinin-antagonisten
PT1192169E (pt) C-pirazoles agonistas do receptor a2a
ATE400558T1 (de) Metabotropische glutamatrezeptor-antagonisten
DE60132799D1 (de) Peroxisom proliferator aktivierten rezeptor alpha agonisten
NO20012450L (no) Holdesegment for svivelanordning
NO20013997D0 (no) Reseptoranalyse
NO20016053D0 (no) IL-8 reseptor-antagonister
NO993131L (no) Svivelinnretning
NO20004503D0 (no) Vitronectin-reseptor-antagonister
NO20016052D0 (no) IL-8-reseptor-antagonister
MA25265A1 (fr) Antagoniste du recepteur de vitronectime.
ATE352299T1 (de) Il-8 rezeptorantagonist
EP1239033A4 (fr) Recepteur de semaphorine
DK199900079A (da) Afskærmningsindretning
NO20015774D0 (no) IL-8 reseptorantagonister
NO20021113D0 (no) Vitronectin-reseptor-antagonister
NO20021295L (no) Nikotinsyreacetylcholin-reseptor
NO995727L (no) Bæreanordning
NO20016102D0 (no) IL-8 reseptorantagonister
NO20016065L (no) IL-8-reseptor-antagonister
IT1319381B1 (it) Dispositivo di collegamento a cerniera per alte